对注意力缺陷过度活动障碍的药物治疗的最新趋势
Haiden A Huskamp1, Alisa B Busch1, Richard G Frank1
1Department of Health Care Policy, Harvard Medical School, Boston (Huskamp, Busch); McLean Hospital, Belmont, Massachusetts (Busch); Brookings Institution, Washington, D.C. (Frank).
Psychiatric services (Washington, D.C.)
|May 28, 2025
概括
在2019年至2023年期间,注意力缺陷/多动症 (ADHD) 药物填充量显著增加. 非兴奋剂的处方急剧增加,可能是由于兴奋剂短缺影响了ADHD治疗的准入.
科学领域:
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
- 精神病学是一个精神病学.
背景情况:
- 注意缺陷/多动症 (ADHD) 诊断和兴奋剂的使用增加了,特别是在成年人中.
- 远程医疗的扩张和兴奋剂药物短缺影响了ADHD治疗模式.
研究的目的:
- 为了比较兴奋剂和非兴奋剂ADHD药物填充率在2019年和2023年之间.
- 为有关ADHD药物治疗处方实践的政策提供信息.
主要方法:
- 利用了2019年和2023年的全国全付费者处方索赔数据.
- 刺激性和非刺激性ADHD药物的计算填充率.
- 根据患者年龄和处方者的专业分析了数据.
主要成果:
- 总ADHD药物填充量从2019年到2023年增加了23.8%.
- 非兴奋剂填充量增加了60.1%,超过了兴奋剂填充量的20.4%的增长.
- 成年人对两种药物类型的填充量增加,而儿科兴奋剂填充量减少了6.5%.
结论:
- 在2019年至2023年期间,ADHD药物填充量大幅增加.
- 发生了非刺激性填充的显著增加,尽管它们不是一线治疗.
- 兴奋剂短缺可能导致非兴奋剂ADHD药物的使用增加.
更多相关视频
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.9K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.4K
相关概念视频
01:30Attention-Deficit/Hyperactivity Disorder
317
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
317
01:28Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
01:26Psychosis: Goals of Pharmacotherapy
216
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
216
01:23Antidepressant Drugs: MAOIs and Other Agents
380
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
380
01:24Mania and Antimanic Drugs: Overview
330
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
330
01:22Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265